Comparative G-Protein-Coupled Estrogen Receptor (GPER) Systems in Diabetic and Cancer Conditions: A Review.

Muhammad, Aliyu; Forcados, Gilead Ebiegberi; Yusuf, Abdurrahman Pharmacy; Abubakar, Murtala Bello; Sadiq, Idris Zubairu; Elhussin, Isra; Siddique, Md. Abu Talha; Aminu, Suleiman; Suleiman, Rabiatu Bako; Abubakar, Yakubu Saddeeq; Katsayal, Babangida Sanusi; Yates, Clayton C.; Mahavadi, Sunila

For many patients, diabetes Mellitus and Malignancy are frequently encountered comorbidities. Diabetes affects approximately 10.5% of the global population, while malignancy accounts for 29.4 million cases each year. These troubling statistics indicate that current treatment approaches for these diseases are insufficient. Alternative therapeutic strategies that consider unique signaling pathways in diabetic and malignancy patients could provide improved therapeutic outcomes. The G-protein-coupled estrogen receptor (GPER) is receiving attention for its role in disease pathogenesis and treatment outcomes. This review aims to critically examine GPER' s comparative role in diabetes mellitus and malignancy, identify research gaps that need to be filled, and highlight GPER's potential as a therapeutic target for diabetes and malignancy management. There is a scarcity of data on GPER expression patterns in diabetic models; however, for diabetes mellitus, altered expression of transport and signaling proteins has been linked to GPER signaling. In contrast, GPER expression in various malignancy types appears to be complex and debatable at the moment. Current data show inconclusive patterns of GPER expression in various malignancies, with some indicating upregulation and others demonstrating downregulation. Further research should be conducted to investigate GPER expression patterns and their relationship with signaling pathways in diabetes mellitus and various malignancies. We conclude that GPER has therapeutic potential for chronic diseases such as diabetes mellitus and malignancy.

ESTROGEN receptors; CARRIER proteins; DIABETES; PEOPLE with diabetes; THERAPEUTICS

Molecules, 2022, Vol 27, Issue 24, p8943

1420-3049

Academic Journal

10.3390/molecules27248943